Bioinformatics Partnering Terms & Agreements -





 Publication date: October 2014 | Version: 4 | Pages: 1,435  

The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.  

  • Trends in bioinformatics partnering deals
  • Deal terms analysis
  • Partnering agreement structure
  • Partnering contract documents
  • Top deals by value
  • Most active dealmakers
  • Average deal terms for bioinformatics

 

The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading healthcare companies.  

The report provides a detailed understanding and analysis of how and why companies enter bioinformatics partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors bioinformatics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 

This report provides details of the latest bioinformatics agreements announced in the healthcare sectors.  

 Bioinformatics is the application of computer science and information technology to the field of biology and medicine. Bioinformatics deals with algorithms, databases, information systems, web technologies, artificial intelligence, information and computation theory, software engineering, data mining, image processing, modeling, simulation, signal processing, discrete mathematics, control systems, and statistics, for generating new knowledge of biology and medicine.

 

 Bioinformatics deals have increased in terms of popularity for partnering in the past decade, as computing power has been embraced in order to speed up the discovery, evaluation and clinical assessment processes.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

This report contains a comprehensive listing of all bioinformatics partnering deals announced since January 2009, including financial terms where available, including over 1500 links to online deal records of actual bioinformatics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

 

The initial chapters of this report provide an orientation of bioinformatics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in bioinformatics dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

                    

Chapter 3 provides a review of the leading bioinformatics deals since 2009. Deals are listed by headline value, signed by big pharma, most active big pharma and big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of bioinformatics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 5 provides a listing of the top big biotech companies with a brief summary followed by a listing of bioinformatics deals where available, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive and detailed review of bioinformatics partnering deals signed and announced since January 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Chapter 7 provides a comprehensive and detailed review of bioinformatics partnering deals signed and announced since January 2009. The chapter is organized by specific bioinformatics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In addition, a comprehensive appendix is provided organized by bioinformatics partnering company A-Z, deal type definitions and bioinformatics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in bioinformatics partnering and dealmaking since 2009.

                                                  

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of bioinformatics technologies and products.

 

 Bioinformatics Partnering Terms and Agreements provides the reader with the following key benefits 

• In-depth understanding of bioinformatics deal trends since 2009

• Access to headline, upfront, milestone and royalty data

• Analysis of the structure of bioinformatics agreements with numerous real life case studies

•Comprehensive access to over 1500  bioinformatics deals entered into by the world’s biopharma companies

• Detailed access to actual bioinformatics contracts enter into by the leading fifty bigpharma companies

• Insight into the terms included in a bioinformatics agreement, together with real world clause examples

• Understand the key deal terms companies have agreed in previous deals

• Undertake due diligence to assess suitability of your proposed deal terms for partner companies


 

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in bioinformatics dealmaking

2.1. Introduction

2.2. Bioinformatics partnering over the years

2.3. Big pharma bioinformatics dealmaking activity

2.4. Big Biotech bioinformatics dealmaking activity

2.5. Most active bioinformatics dealmakers

2.6. Bioinformatics partnering by deal type

2.7. Bioinformatics partnering by stage of development

2.8. Bioinformatics partnering by disease type

2.9. Average deal terms for bioinformatics partnering

2.9.1 Bioinformatics partnering headline values

2.9.2 Bioinformatics deal upfront payments

2.9.3 Bioinformatics deal milestone payments

2.9.4 Bioinformatics royalty rates

 

Chapter 3 – Leading bioinformatics deals

 

3.1. Introduction

3.2. Top bioinformatics deals by value

3.3. Top bioinformatics deals involving big pharma

 

Chapter 4 – Bigpharma bioinformatics deals

 

4.1. Introduction

4.2. How to use bigpharma bioinformatics partnering deals

4.3. Big pharma bioinformatics partnering company profiles

Abbott

Allergan

Amgen

Astellas

AstraZeneca

Baxter International

Bayer

Biogen Idec

Boehringer Ingelheim

Bristol-Myers Squibb

CSL

Daiichi Sankyo

Dainippon Sumitomo

Eisai

Eli Lilly

Galderma

GlaxoSmithKline

Grifols

Hospira

Johnson & Johnson

Lundbeck

Merck & Co

Merck KGaA

Mitsubishi Tanabe

Novartis

Novo Nordisk

Otsuka

Pfizer

Purdue

Roche

Sanofi

Servier

Shire

Takeda

Teva

UCB

Valeant

 

Chapter 5 – Bigbiotech bioinformatics deals

5.1. Introduction

5.2. How to use big biotech partnering deals

5.3. Big biotech bioinformatics partnering company profiles

Array Biopharma

Dendreon

Elan

Galapagos

Genmab

Grifols

Ipsen

Novo Nordisk

Onyx Pharmaceuticals

Spectrum Pharmaceuticals

Vertex Pharmaceuticals

 

Chapter 6 – Bioinformatics dealmaking directory with contracts

 

6.1. Introduction

6.2. By stage of development

Discovery

Formulation

Marketed

Phase III

6.3. By deal type

Asset purchase

Bigpharma outlicensing

Collaborative R&D

Co-market

Contract service

Co-promotion

Development

Distribution

Equity purchase

Licensing

Litigation

Manufacturing

Marketing

Option

Promotion

Research

Settlement

Sub-license

Supply

Termination

6.4. By therapy area

Cardiovascular

Hematology

Hospital care

Infectives

Oncology

 

Chapter 7 – Bioinformatics dealmaking by technology type

Bioinformatics

Software tools

 

Chapter 8 – Partnering resource center

8.1. Online partnering

8.2. Partnering events

8.3. Further reading on dealmaking

About Wildwood Ventures

Current Partnering

Current Agreements

Recent report titles from Current Partnering

Order Form – Reports

 

 

Appendices

 

Appendix 1: By company A-Z

Appendix 2: By stage of development

Appendix 3: By deal type

Appendix 4: By therapy area

 

 

Table of figures

 

Figure 1: Bioinformatics partnering since 2007

Figure 2: Big pharma – top 50 – bioinformatics deals 2007 to 2013

Figure 3: Big pharma biomarker deal frequency – 2007 to 2013

Figure 4: Big biotech – top 50 – bioinformatics deals 2007 to 2013

Figure 5: Big biotech biomarker deal frequency – 2007 to 2013

Figure 6: Active bioinformatics dealmaking activity– 2007 to 2013

Figure 4: Bioinformatics partnering by deal type since 2007

Figure 5: Bioinformatics partnering by deal type since 2007

Figure 6: Bioinformatics partnering by disease type since 2007

Figure 10: Bioinformatics deals with a headline value – by stage of development

Figure 11: Bioinformatics deal headline value distribution – discovery stage, US$million

Figure 12: Bioinformatics deal headline value distribution – preclinical stage, US$million

Figure 13: Bioinformatics deal headline value distribution – phase I stage, US$million

Figure 14: Bioinformatics deal headline value distribution – phase II stage, US$million

Figure 15: Bioinformatics deal headline value distribution – phase III stage, US$million

Figure 16: Bioinformatics deal headline value distribution – regulatory stage, US$million

Figure 17: Bioinformatics deal headline value distribution – marketed stage, US$million

Figure 18: Summary median headline value by stage of development, 2007-2013

Figure 19: Bioinformatics deals with upfront payment values – by stage of development

Figure 20: Bioinformatics deal upfront payment distribution – discovery stage, US$million

Figure 21: Bioinformatics deal upfront payment distribution – preclinical stage, US$million

Figure 22: Bioinformatics deal upfront payment distribution – phase I stage, US$million

Figure 23: Bioinformatics deal upfront payment distribution – phase II stage, US$million

Figure 24: Bioinformatics deal upfront payment distribution – phase III stage, US$million

Figure 25: Bioinformatics deal upfront payment distribution – regulatory stage, US$million

Figure 26: Bioinformatics deal upfront payment distribution – phase marketed stage, US$million

Figure 27: Summary median upfront value by stage of development, 2007-2013

Figure 28: Bioinformatics deals with milestone payments – by stage of development

Figure 29: Bioinformatics deal milestone value distribution, US$million – discovery stage

Figure 30: Bioinformatics deal milestone value distribution, US$million – preclinical stage

Figure 31: Bioinformatics deal milestone value distribution, US$million – phase I stage

Figure 32: Bioinformatics deal milestone value distribution, US$million – phase II stage

Figure 33: Bioinformatics deal milestone value distribution, US$million – phase III stage

Figure 34: Bioinformatics deal milestone value distribution, US$million – regulatory stage

Figure 35: Bioinformatics deal milestone value distribution, US$million – marketed stage

Figure 36: Bioinformatics deals with royalty rates- by stage of development

Figure 37: Bioinformatics deal royalty rates value distribution, US$million – discovery stage

Figure 38: Bioinformatics deal royalty rates value distribution, US$million – preclinical stage

Figure 39: Bioinformatics deal royalty rates value distribution, US$million – phase I stage

Figure 40: Bioinformatics deal royalty rates value distribution, US$million – phase II stage

Figure 41: Bioinformatics deal royalty rates value distribution, US$million – phase III stage

Figure 42: Bioinformatics deal royalty rates value distribution, US$million – regulatory stage

Figure 43: Bioinformatics deal royalty rates value distribution, US$million – marketed stage

Figure 44: Summary median milestone value by stage of development, 2007-2013

Figure 45: Top bioinformatics deals by value since 2007

Figure 46: Top bioinformatics deals signed by big pharma value since 2007

Figure 47: Online partnering resources

Figure 48: Forthcoming partnering events